Nfocus Neuromedical Receives CE Mark For The Cardiovasc Stent-Graft And Delivery System
Palo Alto, CA - Nfocus Neuromedical, Inc. recently announced that the company has received CE mark approval for the CardioVasc Stent-Graft and Delivery System. The CardioVasc Stent-Graft is a minimally invasive device for treating patients with Saphenous Vein Graft Lesions (SVGs) from a previous coronary bypass, Vessel Perforations and Coronary Artery Aneurysms. The CE mark allows Nfocus to begin marketing the CardioVasc Stent-Graft in the European Union, and indicates that the product complies with the appropriate quality and safety standards.
"We are pleased to be able to offer this valuable option to physicians in the European Union for treating diseased bypass grafts. This is an important first step in what we hope to be a series of regulatory approvals in the coming year," said Martin Dieck, President and CEO of Nfocus Neuromedical, Inc.
Saphenous Vein Graft Disease
Saphenous vein graft (SVG) disease has been a problem facing the cardiologist since the early days of coronary artery bypass graft (CABG) surgery. In CABG surgery, a segment of the patient's own leg vein (the "saphenous vein") may be removed and used to create an artificial conduit to bypass areas of blood flow blockage (also known as stenosis or plaque) that have built up in the patient's coronary artery. After CABG surgery, this SVG bypass itself may become blocked over time by the same type of disease that affected the patient's original coronary artery. The result is a need to reopen the diseased SVG vessel and restore flow. This second treatment again can be yet another surgery -- or alternatively, the SVG may be treated via angioplasty and stenting procedures using less-invasive endovascular (catheter) techniques. The CardioVasc Stent-Graft device is a permanent implant delivered via a less-invasive catheter procedure for patients that have a diseased SVG from a previous CABG surgery. The CardioVasc Stent-Graft is not approved in the United States.
Due to the large numbers of patients that have been helped by CABG surgery in past years, there is a large pool of patients with diseased SVG bypass vessels in need of this procedure.
For more information about Saphenous Vein Graft Disease see: http://www.americanheart.org
SOURCE: Nfocus Neuromedical, Inc.